Research Article

To Investigate the Effect of Glucocorticoids on Blood Loss during and after First Total Hip Arthroplasty and Its Safety Meta-Analysis

Chaoqun Wang, Fulin Li, Wenhui Liu, Wenwen Huang, Qinglong Li, and Dong Yin

Youjiang Medical University for Nationalities, Baise, China

Correspondence should be addressed to Dong Yin; 20191051114@stu.ymcn.edu.cn

Received 29 July 2021; Revised 28 September 2021; Accepted 8 November 2021; Published 17 December 2021

Objective. To evaluate the efficacy and safety of topical glucocorticoids for total hip arthroplasty by meta-analysis.

Methods. A computerized search of the Cochrane Library, MEDLINE, EMBASE, and PubMed English databases, as well as Chinese biomedical literature database, VIP Chinese Science and Technology Journal Database, Wanfang database, and Chinese Knowledge Net Database, was performed to include all randomized controlled trials (RCTs) regarding topical glucocorticoid therapy for postoperative bleeding after THA according to the inclusion criteria. The quality evaluation criteria of RCTs, as stated in the Cochrane Handbook for Systematic Reviews of Interventions 4.2.5, were adopted for evaluation, and the meta-analysis was performed using RevMan 5.3.

Results. A total of 10 articles were included, including 1,112 patients: 566 in the topical glucocorticoid group and 546 in the control group. The transfusion rate was 8.43% for topical glucocorticoids and 30.05% for the control group (P < 0.001), and topical glucocorticoids reduced 317.89 ml total blood loss and 76.82 ml invisible blood loss, with statistically significant differences (P < 0.001). The amount of intraoperative blood loss was reduced by topical glucocorticoids, but the difference was not statistically significant (P = 0.83), and the postoperative HB value was increased by topical glucocorticoids, although the difference was statistically significant (P < 0.001). The incidence of DVT and PE after topical glucocorticoid application (3.03%) was greater than that of the control group (2.40%), the difference was not statistically significant (P = 0.54), and the incidence of infection after topical glucocorticoid application (3.03%) was greater than that of the control group (2.40%). The difference was not statistically significant (P = 0.39). Conclusions. Topical glucocorticoids can reduce the transfusion rate and blood loss in THA patients without increasing their risk of thrombosis.

1. Introduction

Total hip arthroplasty (THA) is widely used in many hip diseases, but its blood loss tends to be large, even requiring blood transfusion. Moreover, massive blood loss adversely affects patients and aggravates the burden on multiple organs of the body [1]. In contrast, clinical transfusion may present serious potential risks such as immune reactions, HIV, HBV transmission, and intravascular hemolysis [2]. Therefore, how to reduce the bleeding caused by THA surgery has become an increasing concern and urgent problem for orthopedic surgeons. Until today, several techniques to reduce bleeding have been applied in the clinic, including the treatment of iron, the application of EPO, controlled hypotension, autologous blood reinfusion, and the use of antifibrinolytic drugs [3]. Studies in the 1990s noted that glucocorticoids could effectively reduce surgical bleeding in THA [4]. However, much literature has studied the use of glucocorticoids in THA surgery. Most believe that glucocorticoids can reduce surgical bleeding and blood transfusion in THA and do not increase the risk of DVT. However, there are reports that glucocorticoids are not effective in reducing surgical blood loss in THA. Whether glucocorticoids can effectively reduce bleeding and transfusion in THA surgery and whether they do not increase postoperative deep vein thrombosis and pulmonary embolism remain controversial. This systematic review and meta-analysis aimed to determine whether the use of glucocorticoids in THA surgery is effective in reducing blood loss and transfusion and whether it increases the risk of deep vein thrombosis, pulmonary embolism, and other complications.
2. Materials and Methods

2.1. Literature Search. Two investigators independently searched the English electronic databases, Ovid, PubMed, and ScienceDirect, and the Chinese database, Wanfang and CNKI, from January 1990 to February 2017 [5]. The English language search keywords used were “‘total hip replacement’”, “‘total hip arthroplasty’”, “‘tha’”, “‘thr’”, “‘steroid’”, “‘glucocorticoid’”, “‘dexamethasone’”, “‘corticosteroid’”, “‘cortisone’”, “‘methylprednisolone’”, “‘prednisone’”, “‘betamethasone’”. The Chinese search terms were: “‘total hip arthroplasty’”, “‘glucocorticoids’”, “‘dexamethasone’”, “‘betamethasone’”, “‘methylprednisolone’”, “‘prednisone’”, “‘cortisone’”, “‘hydrocortisone’”.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were request for the full text for full-text reading. abstracts to remove the literature, the reviewer could not screen, and by reading the title of the literature as well as investigators independently retrieved relevant literature for Bone and Joint Loss [9] was manually searched. Two in-

2.3. Quality Assessment of Included Literatures [10]. The methodological quality assessment of the included studies was performed using the criteria for the quality assessment of RCTs in (Cochrane Handbook for Systematic Reviews of Interventions 4. 2. 5): (1) whether the random method selection was correct; (2) whether or not blinding was employed and was the choice of blinding correct; (3) whether allocation concealment; (4) with or without loss to follow-up or withdrawal and with or without loss to follow-up or withdrawal in an intention to treat analysis; and (5) whether the baseline was consistent. A literature review was conducted on the selection of randomized methods, whether blinding was used at the time of randomization, with or without loss to follow-up, or withdrawal.

2.4. Evaluation Index Extraction and Statistical Analysis. A table was developed to extract evaluation indicators, and two investigators extracted data from the literature in accordance with the table content. RevMan 5.3 software was used for statistical analysis. The amount of postoperative drainage, total blood loss, invisible blood loss, intraoperative blood loss, 24 h postoperative HB value, and Hb reduction using topical glucocorticoids were expressed as weighted mean difference (WMD) with 95% confidence interval (CI).

3. Results

3.1. Quantity and Quality Assessment of Retrieved Literature. After the search, 290 articles were identified: 115 in English and 175 in Chinese. After removing duplicates by endnote software, a total of 120 pieces of literature were screened. Sixty-five articles were excluded by reading the title and abstract of the articles, and the remaining by reading the full text, resulting in a total of 10 RCTs after exclusion [12–21]. A total of 1,112 patients were included: 566 in the topical glucocorticoid group and 546 in the control group. The pieces of literature were all published until 2013, the average age of patients was 50.00–76.90 years, the application dose of glucocorticoids was 1–3 g, the application mode was mainly through drainage tube injection [18, 21] and intraoperative infiltration of glucocorticoids [13, 15, 19], the other was joint cavity injection [12, 17, 20], 2 studies did not use drainage tubes [12, 17], 1 study did not mention whether a drain was used or not [12], the rest of the studies used a drain, and the patients’ general conditions are shown in Table 1.

All studies clearly described the random sequence generation method and the method of allocation concealment. Except for Yuan Xiaowei’s study [21], all other studies clearly described the blinding of participants and data statistics. In contrast, incomplete outcome data were clearly described in other studies, except for the study by Yue [15]. For publication bias and other bias, there is less literature that accurately describes it. A detailed description of the included literature quality reviews is presented in Table 2.
Table 1: General condition of included study patients.

| Investigators and years | T/C (people) | Mean age (years) | Intervene | Drainage tube | Transfusion criteria | Prosthesis type |
|-------------------------|--------------|------------------|-----------|---------------|---------------------|----------------|
| Martin [12]             | 25/25        | 62.96/63.92      | 100 mg hydrocortisone, 2 h before operation and push still + 8 h after the second dose | Not used | Hb < 7 | NS |
| Wei [13]                | 102/100      | 60.2/63.9        | 10 mg dexamethasone, 1 h preoperative static push + second dose during surgery | They were opened after 30 min of clipping and removed 24 h after surgery | Hb < 9 | Cementless prostheses |
| Alshryda [14]           | 80/81        | 66/63            | 100 mg hydrocortisone, 2 h before operation push + 8 h after second dose + 8 h after third dose | NS | NS | NS |
| Yue [15]                | 52/49        | 60.9/63.7        | 8 mg or 16 mg dexamethasone at the end of surgery and pushed to rest | They were opened after 30 min of clipping and removed 24 h after surgery | Hb < 7 | Cementless prostheses |
| Jiajing Ye [16]         | 40/40        | 71.5/71.3        | With 125 mg methylprednisolone, i.p. | They were opened 3 h after clipping and removed 24 h after surgery | Hb < 7.5 | Cementless prostheses |
| Ding, min [17]          | 30/30        | 60.00/61.00      | 100 mg hydrocortisone, 2 h before operation push + 8 h after second dose + 8 h after third dose | Not used | Hb < 8 | DePuy joints |
| Yin Han [18]            | 30/30        | 50.00/53.56      | 100 mg dexamethasone, and pushed statically before anesthesia | They were opened after 6 h of clipping and removed at 48 h after surgery | Hb < 7 | Biotype prosthesis |
| Yan, Liang [19]         | 107/107      | 54.10/62.23      | 10 mg dexamethasone, i.p. | Not used | Hb < 7 | Cementless prostheses |
| Fanfucheng [20]         | 56/44        | 66.04/66.50      | 100 mg hydrocortisone, 2 h before operation and push still + 8 h after the second dose | They were opened after 2 h of clipping and removed 24 h after surgery | Hb < 7 | Cementless prostheses |
| Yuan, Xiaowei [21]      | 40/40        | 76.90/76.86      | 10 mg dexamethasone, 1 h preoperative static push + second dose during surgery | The interval was 1 h and was removed 48 h after surgery | Hb < 9 | DePuy total hip instrumentation |

T: glucocorticoid application, C: control group, NS: not mentioned, Hb: hemoglobin.

Table 2: Quality assessment of the included literature.

| Investigators and years | Random sequence | Allocation concealment | Trialists and participants double-blind | Outcome assessment double-blind | Incomplete outcome data | Publication bias | Other biases |
|-------------------------|-----------------|------------------------|----------------------------------------|-------------------------------|------------------------|-----------------|--------------|
| Martin [12]             | Yes             | Yes                    | Yes                                    | Yes                           | Yes                    | Yes             | Unclear      |
| Wei [13]                | Yes             | Yes                    | Yes                                    | Yes                           | Yes                    | Yes             | Unclear      |
| Alshryda [14]           | Yes             | Yes                    | Yes                                    | Yes                           | Yes                    | Yes             | Unclear      |
| Yue [15]                | Yes             | Yes                    | Yes                                    | Unclear                       | Unclear                | Unclear         | Unclear      |
| Jiajing Ye [16]         | Yes             | Yes                    | Yes                                    | Unclear                       | Unclear                | Unclear         | Unclear      |
| Ding, min [17]          | Yes             | Yes                    | Yes                                    | Unclear                       | Yes                    | Unclear         | Unclear      |
| Yin Han [18]            | Yes             | Yes                    | Yes                                    | Unclear                       | Yes                    | Unclear         | Unclear      |
| Yan, Liang [19]         | Yes             | Yes                    | Yes                                    | Unclear                       | Yes                    | Unclear         | Unclear      |
| Fanfucheng [20]         | Yes             | Yes                    | Yes                                    | Unclear                       | Yes                    | Unclear         | Unclear      |
| Yuan, Xiaowei [21]      | Yes             | Yes                    | Unclear                               | Unclear                       | Yes                    | Unclear         | Unclear      |
3.2. Comparison of the Efficacy of Topical versus Intravenous Glucocorticoids

3.2.1. Transfusion Rate. Eight publications analyzed transfusion rates in both cohorts without statistical heterogeneity between studies ($\chi^2 = 2.27, I^2 = 0\%$, $P = 0.95$), using a fixed effects model. Topical glucocorticoid use was associated with a reduced transfusion rate of $8.43\%$ compared with $30.05\%$ in the control group ($RR = 0.28$, $95\%$ CI: $0.20$–$0.39$, $P < 0.001$); see Figure 1.

3.2.2. Total Blood Loss, Hidden Blood Loss, and Intraoperative Blood Loss. Seven papers analyzed postoperative THA blood loss with statistical heterogeneity between studies ($\chi^2 = -20.87, I^2 = 71\%, P = 0.002$) using a random effects model, topical glucocorticoids were found to reduce total blood loss by $317.89$ ml compared to controls with a statistically significant difference ($WMD = -317.89$, $95\%$ CI: $-377.67$ to $-258.12$, $P < 0.001$). Invisible blood loss was analyzed in 1 study, and topical glucocorticoid application reduced the amount of invisible blood loss by $76.82$ ml, which was statistically significant ($WMD = -76.82$, $95\%$ CI: $-89.77$ to $-63.87$, $P < 0.001$). Intraoperative blood loss was analyzed in 3 publications, and the reduction of intraoperative blood loss by topical glucocorticoids was not statistically significant ($WMD = -1.18$, $95\%$ CI: $-12.10$–$9.74$, $P = 0.83$); see Figure 2.

3.2.3. Drainage Volume. The amount of drainage after THA was analyzed in six articles, with significant statistical heterogeneity between studies ($\chi^2 = 3106.36, I^2 = 93\%, P < 0.001$), using a random effects model, topical glucocorticoid application was found to reduce the drainage volume of $140.21$ ml when compared with the control group, with a statistically significant difference ($WMD = -140.21$, $95\%$ CI: $-189.19$ to $-91.22$, $P < 0.001$); see Figure 3.

3.2.4. The HB Value 24 h after Operation as well as the HB Drop Value. Five pieces of literature analyzed the HB value at 24 h after operation without statistical heterogeneity among studies ($\chi^2 = 4.09, I^2 = 2\%, P = 0.39$). Using the fixed effect model, topical glucocorticoids could increase the postoperative HB value, and the difference was statistical. Significance ($WMD = 9.18$, $95\%$ CI: $-7.32$–$11.05$, $P < 0.001$): two articles reported the value of HB decline after surgery, and topical glucocorticoids could reduce the value of HB decline with a significant difference ($WMD = -13.40$, $95\%$ CI: $-15.99$–$-10.81$, $P < 0.001$); see Figure 4.

3.2.5. Comparison of Incidence of DVT and PE Postoperative Infection. The incidence of postoperative DVT and PE was analyzed in eight articles, with no statistical heterogeneity between studies ($\chi^2 = 1.12, I^2 = 0\%$, $P = 0.89$), using a fixed effects model, the incidence of DVT and PE after topical glucocorticoid application (3.03\%) was greater than that of the control group (2.40\%), and the difference was not statistically significant ($RR = 1.27$, $95\%$ CI: $0.59$–$2.74$, $P = 0.54$); see Figure 5. Four articles analyzed the rate of postoperative infection in two groups of patients, the incidence of postoperative infection after topical application of glucocorticoids (3.03\%) was greater than that in the control group (2.40\%), and the difference was not statistically significant ($RR = 2.30$, $95\%$ CI: $0.34$ to $15.38$, $P = 0.39$); see Figure 5.

3.2.6. Hip Function Score. Three studies analyzed the postoperative hip functional score, two studies analyzed the Harris score [22], and one study analyzed the Oxford hip functional score (OHS). For Harris score, topical glucocorticoids could enhance hip function, and the difference was statistically significant ($WMD = 1.12$, $95\%$ CI: $0.39$–$1.84$, $P = 0.003$). For OHS, there was no significant difference in the effect of topical glucocorticoids compared with the control group ($WMD = -2.80$, $95\%$ CI: $-7.04$–$1.44$, $P = 0.20$); see Figure 6.

3.2.7. Subgroup Analysis. Because of significant heterogeneity in total blood loss and drainage volume, studies with general data found inconsistency in the doses of topically applied glucocorticoids, analyzed according to total doses of 1 g, 2 g, and 3 G, with 3 publications included at a total dose of 1 g [15, 18, 20], with statistical heterogeneity between studies ($\chi^2 = 7.05, I^2 = 72\%, P = 0.03$). Topical application of glucocorticoids reduced $367.71$. At a total dose of $3$ G [12, 14], there was no statistical heterogeneity between studies ($\chi^2 = -1.52, I^2 = 34\%, P = 0.22$), and topical glucocorticoids reduced $358.28$ ml total blood loss with a statistically significant difference ($WMD = -358.28$, $95\%$ CI: $-26$ to $-286.31$, $P < 0.001$).

4. Discussion

Accelerated recovery after surgery (ERAS) refers to the provision of highly efficient and high-quality medical services after a series of simple and effective perioperative management measures that reduce surgical, traumatic stress reaction and postoperative complications, alleviate patient suffering, and shorten hospital stay [23, 24]. Numerous studies have confirmed that eras are effective in reducing postoperative complications of joint arthroplasty, reducing the length of hospital stay, and improving patient satisfaction [25]. Moreover, one of the key points of eras application in joint arthroplasty is to reduce postoperative stress and inflammation [26].

The inflammatory response is one of the important mechanisms underlying the stress response after surgical trauma. It is closely related to postoperative pain, postoperative nausea and vomiting (PONV), fatigue, muscle strength loss, sleep disturbance, and so on. Therefore, alleviating the postoperative inflammatory response can help reduce postoperative complications, shorten hospital stay, and achieve the goal of accelerating rehabilitation after joint replacement [27]. Glucocorticoids, as a commonly used and effective agent to inhibit inflammatory responses, have been widely used in various types of surgery and are proven to have good effects [28, 29]. In recent years, domestic and
### 2.1.1 Total blood loss

| Study or Subgroup | Experimental Total | Control Total | Weight (%) | Risk Ratio M/H, Fixed, 95%CI |
|-------------------|--------------------|---------------|------------|-----------------------------|
| Alshryda S 2013   | 10 80 26 81        |               | 20.3       | 0.39 [0.20, 0.75]            |
| Wei W 2014        | 6 100 26 102       |               | 20.2       | 0.24 [0.10, 0.55]            |
| Yue C 2014        | 3 52 11 49         |               | 8.9        | 0.26 [0.08, 0.87]            |
| Min D 2014        | 6 30 19 30         |               | 14.9       | 0.32 [0.15, 0.68]            |
| Fu Cheng F 2014   | 6 55 20 44         |               | 17.5       | 0.24 [0.11, 0.55]            |
| Jiajing Y 2015    | 2 40 6 40          |               | 4.7        | 0.33 [0.07, 1.55]            |
| Han Y 2014        | 2 30 8 30          |               | 6.3        | 0.25 [0.06, 1.08]            |
| Xiao Wei Y 2015   | 1 40 9 40          |               | 7.1        | 0.11 [0.01, 0.84]            |
| Total (95%CI)     | 427 416 100.0      |               |            | 0.28 [0.20, 0.39]            |

Total events: 36 125

Heterogeneity: Chi² = 2.27, df = 8 (P = 0.95); I² = 0%

Test for overall effect: Z = 7.39 (P < 0.00001)

### 2.1.2 Invisible blood loss

| Study or Subgroup | Experimental Total | Control Total | Weight (%) | Risk Ratio M/H, Fixed, 95%CI |
|-------------------|--------------------|---------------|------------|-----------------------------|
| Xiao Wei Y 2015   | 10 80 26 81        |               | 20.3       | 0.39 [0.20, 0.75]            |

### 2.1.3 Intraoperative blood loss

| Study or Subgroup | Experimental Total | Control Total | Weight (%) | Risk Ratio M/H, Fixed, 95%CI |
|-------------------|--------------------|---------------|------------|-----------------------------|
| Min D 2014        | 10 80 26 81        |               | 20.3       | 0.39 [0.20, 0.75]            |

### Figure 1: Comparison of transfusion rates between the two groups.

![Comparison of transfusion rates between the two groups.](image1)

### Figure 2: Comparison of total and invisible postoperative blood loss as well as intraoperative blood loss between the two groups.

![Comparison of total and invisible postoperative blood loss as well as intraoperative blood loss between the two groups.](image2)
foreign scholars have conducted relevant studies on the systemic application of glucocorticoids in TKA, but high-quality, relevant studies were few, the level of evidence was low, and the results were still controversial [30]. It is believed that systemic administration of glucocorticoids can effectively relieve pain, reduce PONV symptoms, and accelerate recovery in the perioperative period of total knee arthroplasty (TKA) [31]. There have also been studies with reservations regarding the efficacy of systemic glucocorticoid use in TKA [32].

THA has become a more mature surgical technique in the clinic. However, it is a traumatic treatment, and postoperative fever, infection, deep vein thrombosis, prosthesis loosening, fracture, dislocation, limb malalignment, and heterotopic ossification often occur, especially with fever, infection, and deep vein thrombosis [33]. In the early postoperative period, appropriate rehabilitation training is necessary to promote venous return of the affected limb, reduce swelling, prevent deep vein thrombosis of the lower extremity, reduce adhesion to surrounding tissues, increase the strength of surrounding muscle groups, enhance joint stability and the weight-bearing capacity of bone, shorten rehabilitation time, and improve the functional status and quality of life of the limbs. Reducing the incidence of various types of complications and so on has a very important role [34]. However, patients often experience pain affecting normal rest, sleep, and diet, which can affect wound healing and postoperative functional exercises, severely affecting hip

| Study or Subgroup | Mean (SD) | Total | Mean (SD) | Total | Weight (%) | IV, Random , 95%CI |
|-------------------|-----------|-------|-----------|-------|------------|-------------------|
| **7.1.1 Hb value at 24h after operation** |
| Alshryda S 2013   | 106.2 (13.4) | 80    | 97.8 (14.5) | 81    | 18.6 | 8.40 [4.09, 12.71] |
| Min D 2014       | 95 (15) | 30    | 81 (12) | 30    | 7.3 | 14.00 [7.13, 20.87] |
| Fu Cheng F 2014  | 88.57 (8.86) | 55    | 81.65 (10.43) | 44    | 23.1 | 5.92 [3.05, 10.78] |
| Xiao Wei Y 2015  | 100.53 (9.13) | 40    | 91.83 (8.77) | 40    | 22.5 | 8.70 [4.78, 12.62] |
| Liang Y 2015     | 108.24 (14.89) | 107   | 97.56 (10.81) | 107   | 28.5 | 10.68 [7.19, 14.17] |
| **Subtotal (95%CI)** | 312 | 302   | 100.0 | 9.18 [7.32, 11.05] |
| Heterogeneity: Chi² = 4.09, df = 4 (P = 0.39); I² = 2% |
| Test for overall effect: Z = 9.68 (P < 0.00001) |

| Study or Subgroup | Mean (SD) | Total | Mean (SD) | Total | Weight (%) | IV, Random , 95%CI |
|-------------------|-----------|-------|-----------|-------|------------|-------------------|
| **7.1.2 Hb drop in value** |
| Yue C 2014       | 40.02 (9.74) | 52    | 53.27 (4.79) | 49    | 76.0 | -13.25 [-18.62, -10.28] |
| Han Y 2014       | 24.9 (10.77) | 30    | 38.78 (10.1) | 30    | 24.0 | -13.88 [-19.16, -8.60] |
| **Subtotal (95%)** | 82 | 100.0 | 13.40 [-15.99, -10.81] |
| Heterogeneity: Chi² = 0.05, df = 2 (P = 0.85); I² = 0% |
| Test for overall effect: Z = 10.16 (P < 0.00001) |
| Test for subgroup difference: Chi² = 192.97, df = 2 (P < 0.00001); P = 99.6% |

Figure 3: Comparison of Hb values and Hb decline at 24h after operation between two groups.

Figure 4: Comparison of postoperative drainage volume between two groups.
functional recovery and patient satisfaction [35]. Currently, adjuvant therapy with glucocorticoids (GC) is applied to patients undergoing surgical procedures clinically, in the perioperative period to reduce pain and reduce complications [36].

GC has many physiological and pharmacological effects, which mainly include the following: (1) obviously suppressing the inflammatory response induced by various factors, inhibiting the movement of inflammatory cells to the site of inflammation, stabilizing the lysosomal membrane, reducing serotonin and IL-1β, releasing inflammatory mediators such as IL-6, TNF-a, and bradykinin, thereby alleviating symptoms such as redness, heat, and pain [37]; (2) moderating the body’s response to endotoxin, inhibiting the hypothalamic response to pyrogens, inhibiting the production and release of leukocyte pyrogens, decreasing the sensitivity of thermoregulatory centers to pyrogens, and having an antipyretic effect on hyperthermia [38]; (3) antishock effect and the effect of increasing the body’s stress capacity; and (4) inhibiting the proliferation of fibroblasts, reducing the production of collagen fibers, and so on.

The results of the meta-analysis showed that topical glucocorticoids, which reduced the blood transfusion rate, total blood loss, and invisible blood loss; increased postoperative Hb; decreased HB drop values; and enhanced hip function, did not increase the incidence of postoperative DVT, the incidence of wound infection, or the OHS score and were not statistically significant for intraoperative blood loss.

THA is associated with significant blood loss due to procedures such as intraoperative muscle transection plus reaming, which can cause significant overt blood loss. On the contrary, invisible blood loss is the focus of attention among orthopedic surgeons in recent years, with studies indicating that invisible blood loss accounts for 60% of total blood loss, and the mechanism responsible for invisible blood loss may have hemolysis caused by intraoperative RBC rupture. The

| Study or Subgroup | Experimental Events | Control Events | Risk Ratio M-H, Fixed, 95%CI | Risk Ratio M-H, Fixed, 95%CI |
|-------------------|---------------------|----------------|------------------------------|------------------------------|
| Alshryda S2013    | 2 80 2 81 18.1 1.01 [0.15, 7.01] |
| Yue C 2014       | 1 52 0 49 4.7 2.83 [0.12, 67.87] |
| Han Han 2014     | 0 40 0 40 Not estimable |
| Liang Y2015      | 9 107 8 107 54.5 1.50 [0.55, 43.07] |
| Subtotal (95%CI)  | 429 416 100.0 1.27 [0.59, 2.74] |
| Total events     | 13 |
| Heterogeneity: Chi² = 0.04, df = 2 (P = 0.88); I² = 0% |

Test for overall effect: Z = 0.81 (P = 0.54)

| Study or Subgroup | Experimental Events | Control Events | Risk Ratio M-H, Fixed, 95%CI |
|-------------------|---------------------|----------------|------------------------------|
| Alshryda S2013    | 2 80 1 81 65.9 2.02 [0.19, 21.89] |
| Yue C 2014       | 1 52 0 49 34.1 2.83 [0.12, 67.87] |
| Han Han 2014     | 0 30 0 30 Not estimable |
| XiaoWei Y2015    | 0 40 0 40 Not estimable |
| Subtotal (95%CI)  | 202 200 100.0 2.30 [0.34, 15.38] |
| Total events     | 3 1 |
| Heterogeneity: Chi² = 0.04, df = 2 (P = 0.88); I² = 0% |

Test for overall effect: Z = 0.87 (P < 0.00001)

Test for subgroup difference: Chi² = 0.33, df = 2 (P < 0.00001); I² = 0%

Figure 5: Comparison of the incidence of postoperative DVT as well as PE between the two groups.
interstitial exudation doctrine [39], with studies suggesting a fibrinolytic activation period after 24 h of surgery, further increases postoperative blood loss [40]. Glucocorticoids, as a commonly used and effective agent to inhibit inflammatory responses, have been widely used in various types of surgery and are proven to have good effects [41]. Although glucocorticoids theoretically do not increase the amount of fibrin, Li et al. [42, 43] suggested that intravenous glucocorticoids inhibit fibrinolysis throughout the body, combined with the fact that hip replacement patients, who are mostly elderly patients, would increase the incidence of postoperative DVT and PE. Topical application of glucocorticoids concentrates glucocorticoid drug concentrations around the joint cavity via various routes [44]. In this study, the transfusion rate of topical glucocorticoids was 8.43% compared with 30.05% in the control group (RR = 0.28, 95% CI: 0.20–0.39, P < 0.001), although Wang [45] concluded by meta-analysis of randomized controlled trials and retrospective comparative studies that topical glucocorticoid administration could reduce the transfusion rate without increasing the rates of DVT and PE. However, the Chinese databases were not searched, and only 4 RCTs were included, which did not compare invisible blood loss and postoperative hip function scores.

The strengths of this study are that only RCTs were included; non-RCTs were excluded; and invisible blood loss, 24 h postoperative HB value, and hip function score were compared, which strengthened the evidence grade and further demonstrated that topical glucocorticoids could reduce perioperative total blood loss and invisible blood loss, increase postoperative HB value, and enhance the Harris score in hips. Postoperative DVT and PE are more dangerous postoperative complications, which threaten the life safety of patients once they form a PE [46]. The results of the eight included articles showed no significant difference in the incidence of DVT and PE after topical glucocorticoids, which suggests that topical glucocorticoids do not increase the incidence of postoperative thrombus while reducing postoperative blood loss. Nevertheless, the results were consistent in the study of [47], which compared seven series of hip replacement patients with topical glucocorticoids. Topical glucocorticoids can reduce postoperative blood loss without increasing the chance of postoperative thrombosis in patients with total hip replacement. Compared with the intravenous application of glucocorticoids, the topical application of glucocorticoids can reduce the systemic blood concentration and avoid the occurrence of thrombus [48]. In conclusion, topical glucocorticoids can reduce postoperative blood loss and reduce the rate of blood transfusion without increasing postoperative thrombosis in THA patients. However, because various studies used different doses and different methods of topical application, the direction of future research should focus on the optimal dose of glucocorticoids and the efficacy of topical glucocorticoids compared with intravenous glucocorticoids to explore the most applicable volume and optimal application route.

Although long-term administration of glucocorticoids has an increased risk of infection, gastrointestinal bleeding, and so on, short perioperative glucocorticoid administration is not associated with such risks [49]. A meta-analysis involving 71 studies confirmed that short perioperative glucocorticoid administration does not increase the risk of
postoperative complications in patients [50]. Currently, although relevant studies on the systemic application of glucocorticoids in THA all agree that the glucocorticoid group has the same postoperative complication rate as the control group, some studies have found that local application of glucocorticoids in the hip joint cavity may increase the risk of postoperative infection [51]. Therefore, we still need to pay more attention before definitive conclusions can be drawn.

This study mainly has 3 deficiencies: (1) the included literature has a small sample size, which is difficult to cause bias to the results and generates uncertain conclusions [52]; (2) because the statistical results of some indicators such as hip function and thrombotic markers were few, a meta-analysis could not be performed and only descriptive statistics could be performed; and (3) the limited number of included studies in the literature was insufficient to perform subgroup analyses targeting high or low glucocorticoid doses. However, this systematic review and meta-analysis is the first to synthesize the relevant, high-quality literature to date, perform a normative meta-analysis according to PRISMA principles and processes, and comprehensively analyze the use value of systemic glucocorticoids in THA accelerated rehabilitation. We believe that the results of this study will be an important guiding value for clinical work [53].

The results of the present study suggest that topical glucocorticoids can reduce the transfusion rate and blood loss in THA patients without increasing their risk of thrombosis.

Data Availability

The original data could be obtained from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research was supported by grants from the Guangxi Scientific Research and Technology Development Program (AB16380230), Guangxi Medical and Health Project (Z2016574), and Health Commission of Guangxi Zhuang Autonomous Region (Z20200911).

References

[1] S. Chen and N. Norway, “Clinical efficacy of cefixime and cefaclor in combination with low-dose glucocorticoids in children with acute bronchitis, respectively,” Chinese Maternal and Child Health, vol. 36, no. 13, pp. 3000–3002, 2021.

[2] L. Xu, L. Zhou, F. Zheng, J. Zhao, Q. Xing, and G. Ren, “Clinical efficacy of combined cortisosteroid and terbutaline nebulization in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on lung function,” Journal of Practical Cardio Cerebrovascular Disease, vol. 29, no. 7, pp. 18–23, 2021.

[3] X. Xie, B. Xie, Z. Zheng, L. Xu, L. Liang, and Z. Ye, “Efficacy and safety study of cyclophosphamide intravenous shock combined with glucocorticoid therapy for idiopathic membranous nephropathy,” Journal of the Third Military Medical University, vol. 43, no. 12, pp. 1173–1178, 2021.

[4] F. Xiaoran, L. Li, and L. Xue, “A case of herpes like pemphigus foliaceus treated with minocycline hydrochloride combined with topical glucocorticoids,” Chinese Journal of Leprosy Dermatology, vol. 37, no. 7, pp. 451–453, 2021.

[5] Guangdong Provincial Pharmaceutical Association, “Expert consensus on perioperative glucocorticoid medicine and pharmacy,” 2021, http://kns.cnki.net/kcms/detail/44.1650.R.20210621.1333.002.html.

[6] S. Gong, “Clinical effects of adjuvant treatment with low-dose glucocorticoids for Mycoplasma pneumoniae pneumonia in children,” Journal of clinical rational drug use, vol. 14, no. 17, pp. 129–131, 2021.

[7] H. Li, L. Gao, C. X. Zhang, D. Zhang, and H. Hou, “Advances in the pharmaceutical mechanism of glucocorticoid induced osteoporosis,” Chinese Journal of Osteoporosis, vol. 27, no. 6, pp. 910–913, 2021, + 921.

[8] Y. Zhou, A. I. Zhang, Ya Liu, and Z. Wang, “Plasma jet coupled activated carbon fiber for removal of glucocorticoids from water,” Chemical advances, pp. 1–10, 2021.

[9] M. Mingham, “Analysis of the effect of glucocorticoids on bone mineral density in patients with rheumatic immune disease,” Contemporary medicine, vol. 27, no. 17, pp. 34–35, 2021.

[10] S. Z. Gong, “Observations on the efficacy and safety of montelukast sodium combined with glucocorticoids for the treatment of pediatric asthma,” Jilin Medical, vol. 42, no. 6, pp. 1417–1418, 2021.

[11] W. Wu, “Efficacy of glucocorticoids combined with terbutaline for treating chronic obstructive pulmonary disease,” Modern pharmaceutical applications in China, vol. 15, no. 11, pp. 169–171, 2021.

[12] X. Wang, Y. Zhang, L. Zhou, and X. Li, “Glucocorticoid receptor gene polymorphisms and their impact on treatment in patients with AECOPD,” Journal of Clinical Rational Drug Use, vol. 14, no. 16, pp. 9–11, 2021.

[13] X. Zhang, L. Yang, B. Tang, H. Hu, and L. Li, “Clinical efficacy of adjuvant glucocorticoid treatment of Mycoplasma lobar pneumonia in children,” Journal of Clinical Rational Drug Use, vol. 14, no. 16, pp. 18–20, 2021, + 23.

[14] J. M. Chen, “Clinical characteristics and prognosis of community acquired pneumonia in patients receiving long-term glucocorticoid treatment,” Journal of Clinical Rational Drug Use, vol. 14, no. 16, pp. 76–77, 2021.

[15] J. Kun and X. Xiao, “Yunqiu Li abstract the current status of oral glucocorticoids in the perioperative period of chronic sinusitis with nasal polyps,” Journal of Otolaryngology and Eye, Shandong University, 2021, http://kns.cnki.net/kcms/detail/37.1437.R.20210608.0853.002.html.

[16] X. Zhang, Y. Zheng, L. Gui, J. Huang, Y. F. Quan, and S. Lin, “Comparative clinical efficacy of locally injected platelet rich plasma or glucocorticoid combined with extracorporeal shock wave therapy for lateral epicondylitis of the humerus,” Zhonghua geriatric orthopaedics and rehabilitation electronic journal, vol. 7, no. 3, pp. 158–163, 2021.

[17] L. Wang, W. Li, J. Zhou, J. J. Chen, and H. Zhao, “Mindfulness Li and Fang Ling Li clinical study of Xiaojing Huo spatum Decotion plus and minus combined glucocorticoid therapy for bronchial asthma in elderly patients,” Shaanxi traditional Chinese medicine, vol. 42, no. 6, pp. 724–727, 2021.
[18] L. Xie, L. Shen, and B. Huang, “Selective use of glucocorticoids combined with gamma globulin for treatment of gamma globulin unresponsive Kawasaki disease,” Journal of Pediatric Pharmacy, vol. 27, no. 6, pp. 24–27, 2021.

[19] L. Cui, Z. Chen, V. L. Zhang, F. Lu, and Y. J. Zhu, “Correlation between serum microRNA-206 and Clara cell protein 16 expression levels and glucocorticoid efficacy in children with bronchial asthma,” Journal of Pediatric Pharmacy, vol. 27, no. 6, pp. 7–11, 2021.

[20] S. Chen, “A review of glucocorticoid induced osteoporosis,” Journal of Shandong University, http://kns.cnki.net/kcms/detail/37.1390.R.20210531.1145.008.html, 2021.

[21] J. He and J. Li, “A review of tertiary prevention and treatment strategies for osteonecrosis of the femoral head after novel coronavirus pneumonia,” Journal of practical heart and lung and vascular disease, vol. 28, no. 9, pp. 1–5, 2020.

[22] L. Chen, F. Feng, H. Feng, H. Li, and J. Gu, “Efficacy of total hip replacement for the treatment of osteonecrosis of the femoral head in patients with systemic lupus erythematosus,” Chinese Journal of bone and joint surgery, vol. 13, no. 2, pp. 143–147, 2020.

[23] C. Xu, X. Yuwen, M. Song, P. Xu, C. Lu, and W. Chen, “Analysis of population characteristics and clinical characteristics of patients undergoing total hip arthroplasty for osteonecrosis of the femoral head,” Traditional Chinese medicine orthopedic bone, vol. 32, no. 1, pp. 51–55, 2020.

[24] G. Kong, W. H. Ma, and T. D. Zhang, “The hip-preserving treatment strategy and efficacy of steroid-induced femoral head necrosis,” Chinese Journal of Orthopedics, vol. 39, no. 23, 2019.

[25] W. M. Fu, B. Y. Liu, B. J. Wang, and D. W. Zhao, “Hip preserving treatment strategy and efficacy of steroid induced femoral head necrosis,” Chinese Journal of Orthopedics, no. 23, pp. 1424–1425, 2019.

[26] W. Xie, D. sclerae, M. X. Gao, and Z. Zhen, “The hip-preserving treatment strategy and efficacy of steroid-induced femoral head necrosis,” Chinese Journal of Orthopedics, vol. 32, no. 7, pp. 189–190, 2019.

[27] Q. Zhang, Hormonal Induced Femoral Head BMEC Injury, Exosomes, microRNA Expression and Intervention Effects of Icarin and Shock Wave, Peking Union Medical College, Beijing, China, 2019.

[28] L. shuayongming, f. Zeng, and S. Tu, “Analysis of clinical characteristics of hormone induced osteoporotic intertrochanteric femoral fracture,” Chinese Journal of bone and joint injuries, vol. 34, no. 2, pp. 152–154, 2019.

[29] F. Liu, h Peng, X. Zhang, J. Yang, Z. sun, and F. Wu, “Efficacy of procoagulant glucocorticoids for the prevention of orthostatic hypotension after total hip arthroplasty,” Journal biological orthopaedic materials and clinical research, vol. 16, no. 01, pp. 28–32, 2019.

[30] X. Zhu, “Efficacy of glucocorticoid + terbutaline on acute exacerbation stage of chronic obstructive pulmonary disease and effects on pulmonary function indicators,” Road to Health, vol. 17, no. 7, p. 81, 2018.

[31] P. F. Mei, Exploring the Mechanism of Glucocorticoid Induced Femoral Head Lesions Based on Bone Development in Rats and Mice, Guangdong Pharmaceutical University, Guangzhou, China, 2018.

[32] Z. Zhang, A Retrospective Study of the Efficacy of Bone Flap Transplantation Combined with Porous Tantalum Rod in Steroid Induced Femoral Head Necrosis, Dalian Medical University, Dalian, China, 2018.

[33] B. Xu and F. Pei, “The role of glucocorticoids in accelerated rehabilitation of hip and knee arthroplasty,” Chinese Journal of Bone and Joint Surgery, vol. 10, no. 3, pp. 259–264, 2017.

[34] H. B. Luo, H. Lan, and J. T. Wang, “Effects of perioperative use of glucocorticoids on immune function and rehabilitation in patients undergoing hip replacement,” Modern Health, vol. 10, no. 3, 2017.

[35] W. Jon, J. long, Y. J. Liu et al., “A systematic review and meta-analysis of the effects of systemic glucocorticoids on accelerated rehabilitation in total knee arthroplasty,” Chinese Journal of Bone and joint surgery, vol. 10, no. 2, pp. 117–122, 2017.

[36] P. H. Chensen, “A review of the pathological mechanisms of glucocorticoid induced osteonecrosis in adults,” Orthopedics, vol. 8, no. 2, pp. 157–160, 2017.

[37] W. Zhou, G. Huang, J. Y. Chen, X. Wei, and S. Huang, “Long term hormonal effect study of perioperative period in elderly patients undergoing joint replacement surgery,” Shaanshi Medical Journal, vol. 45, no. 8, pp. 949–950, 2016.

[38] X. Liu, Treatment of Sojia with Glucocorticoids and Serum 25 (OH) D_3 Studies of Level Variation, Jilin University, Changchun, China, 2016.

[39] L. Yu, G. Zhang, B. Ni, and J. N. Zhao, “Meta analysis of intravenous glucocorticoids for the improvement of PONV and pain after knee arthroplasty,” Journal of Clinical and Pathology, vol. 35, no. 11, pp. 1985–1991, 2015.

[40] X. Chen, T. Huang, Q. Liu, Y. Tan, and G. U. I. Zizhen, “Analysis of the effects of perioperative care of hip replacement after renal transplantation on patients’ pain and complications,” Chongming Medical Science, vol. 44, no. 30, pp. 4316–4317, 2015, + 4320.

[41] L. Wang, Y. S. Liu, and S. Liu, “Pathogenesis of glucocorticoid induced osteonecrosis of the femoral head,” Zhonghua Za Zhi of injury and repair (Electronic), vol. 10, no. 5, pp. 439–445, 2015.

[42] C. Jiao, S. Xu, Y. Tu, Z. Liu, and S. Li, “Patients with nephrotic syndrome with aseptic femoral head necrosis,” Journal of Nephrology and Kidney Transplantation in Dialysis, vol. 24, no. 4, pp. 307–312, 2015.

[43] Y. Lu, Q. Yu, W. Guo, L. Cheng, and P. Li, “Effects of glucocorticoids on the function of microvascular endothelial cells in human femoral head bone,” Chinese Journal of Orthopedic Surgery, vol. 23, no. 15, pp. 1400–1405, 2015.

[44] Li Q. Deng, P. Deng, X. Fu et al., “Perioperative management of systemic lupus erythematosus with osteonecrosis of the femoral head undergoing total hip arthroplasty,” West China Medical Center, vol. 30, no. 5, pp. 865–868, 2015.

[45] X. Wang, A Study on the Characteristics and Associated Risk Factors of Osteonecrosis of the Femoral Head after Renal Transplantation, Tianjin Medical University, Tianjin, China, 2015.

[46] Y. Hong, Z. Gu, Y. Feng, and J. Yan, “Effect of propofol intravenous anesthesia combined with lumbar epidural anesthesia on hip joint fracture surgery,” Chinese Journal of Clinical Pharmacology, vol. 37, no. 13, pp. 1651–1654, 2021.

[47] J. Suyi and J. Liu, “Effect of nursing care combined with ankle pump movement on the prevention of deep vein thrombosis in patients with lower extremity fracture,” Journal of Rare and Rare Diseases, vol. 28, no. 4, pp. 92–93, 2021.

[48] X. Ma and H. Han, “Clinical efficacy and safety of Qiangji Zhitong Decoction combined with suture embedding at Jiaji point in the treatment of ankylosing spondylitis (damp-heat type),” Chinese Medicine Information, no. 7, pp. 61–64, 2021.
[49] H. Huang, Y. Gao, K. Nie, and L. Wang, “Macrophage migration inhibitory factor mediates the activation of NLRP3 inflammasome in microglia induced by MPP+/MPTP,” Journal of Southern Medical University, vol. 41, no. 7, pp. 972–979, 2021.

[50] M. Zhao and S. Li, "Non-pharmaceutical interventions to improve chronic comorbidities related mechanism research progress," China General Medicine, http://kns.cnki.net/kcms/detail/13.1222.R.20210717.1534.014.html, 2021.

[51] H. M. Wang, "The interaction mechanism and intervention status of mental disorders and diabetes mellitus," vol. 1-8, 2021, http://kns.cnki.net/kcms/detail/51.1356.R.20210721.0957.038.html.

[52] X. Pei and H. Guan, "The mechanism and clinical management of thyroid dysfunction induced by amiodarone and iodine-containing contrast agent," Medical review, no. 14, pp. 2808–2813, 2021, http://kns.cnki.net/kcms/detail/11.3553.R.20210714.1658.036.html.

[53] J. Ma, Y. A. N. G. Pei, and K.-z. Wang, "Glucocorticoids inducing vascular repair disorders under hypoxia via inhibiting cell migration and autocrine/paracrine:bioinformatical analysis combined with cytological experiment," Chinese Journal of Biomedical Engineering, vol. 30, no. 2, pp. 75–92, 2021.